So, BioXcel Therapeutics Inc. (BTAI) shares are taking a step back on Friday. This comes after the stock got a nice little boost on Thursday. Why the sudden mood swing? It's all about some fresh data from the lab.

The stock's movement follows the release of positive topline results from a Phase 2 study evaluating BXCL501 for treating opioid withdrawal symptoms.

Here's the good part: the trial, led by Columbia University, indicated that BXCL501 may be as effective as or superior to BioCorRx Pharmaceuticals Inc.'s lofexidine for reducing withdrawal symptoms, showcasing a favorable tolerability profile. In other words, their experimental drug might work as well as, or better than, a drug that's already out there for this problem.

In the study, patients receiving BXCL501 experienced over a 30% reduction in withdrawal symptoms compared to a placebo, with significant improvements observed on days three and four. The data reinforce BXCL501's potential as a versatile treatment option, suggesting applicability across multiple indications, including acute agitation associated with bipolar disorder and schizophrenia. So, it's not just a one-trick pony; the company sees a broader path forward for this drug.

Now, for the less fun part: the stock chart. The stock is currently trading 3.9% below its 20-day simple moving average (SMA) and 17.9% below its 100-day SMA, indicating a struggle to gain traction in the short to medium term. Shares have decreased approximately 41.24% over the past 12 months and are currently positioned closer to their 52-week lows than highs.

Some technical indicators offer a mixed picture. The RSI is at 46.86, which is considered neutral territory, suggesting the stock is neither overbought nor oversold. Meanwhile, MACD is at -0.0166, above its signal line at -0.0272, indicating bullish momentum despite the overall bearish trend. So, the short-term momentum might be trying to turn positive, but it's fighting against a longer-term downtrend.

At the end of the day, it looks like a classic case of "buy the rumor, sell the news"—or at least, take some profits after the news. The science seems promising, but the market is reminding everyone that the stock has had a tough year and needs to prove it can build on this positive development.

BTAI Price Action: BioXcel Therapeutics shares were down 5.89% at $1.52 at publication on Friday, according to market data.